Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

Geoffrey Ku • 21 Jan 2021
ASCO GI 2021
Esophageal Cancer Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Durvalumab FOLFOX Telomelysin

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a study evaluating durvalumab, an anti-PD-L1 antibody, and PET-directed chemoradiation (CRT) after induction FOLFOX for patients with esophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).

More from Geoffrey Ku

1:34
Zanidatamab and chemotherapy in HER2+ gastroesophageal cancer
Geoffrey Ku • 17 Apr 2023
1:50
Durvalumab and PET-directed chemoradiation in advanced esophageal cancer
Geoffrey Ku • 17 Apr 2023
1:15
How do we treat GEJ carcinoma resistant to HER2 targeted therapies?
Geoffrey Ku • 17 Apr 2023
1:36
Cinrebafusp alfa with ramucirumab and paclitaxel in HER+ GEJ cancer
Geoffrey Ku • 17 Apr 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals